Retatrutide delivers 28.3% weight loss in Phase 3 obesity trial
Roughly 45% of the 2,500 patients reached 30% or more weight loss, a level Lilly's science chief said had previously required bariatric surgery.
MH
By Maren Holt · Senior Reporter, GLP-1
May 21 03:00 ETSource: CNBC
The wire
- 01Lilly said the highest dose of weekly retatrutide produced 28.3% average weight loss, or 70.3 pounds, over 80 weeks versus 2.2% with placebo among patients who stayed on drug.
- 02The triple agonist would sit above Zepbound's roughly 20% to 22% range and is central to Lilly's plan to hold share against Novo Nordisk; a 4 mg dose gave 19% loss.
- 03Higher rates of nausea and diarrhea appeared at the top dose; results are company-reported, filing has not occurred, and TD Cowen previously estimated $3.8 billion in 2030 sales.
From the source
Read at cnbc.comEli Lilly says next-generation weight loss drug clears crucial obesity trial
Eli Lilly on Thursday said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses.